Loading...
XKRX001065
Market cap380mUSD
Dec 23, Last price  
29,600.00KRW
1D
-0.34%
1Q
-1.82%
Jan 2017
39.05%
Name

JW Pharmaceutical Corp

Chart & Performance

D1W1MN
XKRX:001065 chart
P/E
18.39
P/S
0.91
EPS
1,609.87
Div Yield, %
1.30%
Shrs. gr., 5y
-1.83%
Rev. gr., 5y
6.86%
Revenues
748.53b
+9.38%
385,010,282,000437,648,380,000455,146,860,000443,275,672,000431,007,281,000397,084,758,770394,182,301,740412,791,234,930434,352,380,160467,465,120,990502,918,586,610537,181,974,040511,335,342,730547,335,707,800606,584,944,780684,351,099,240748,526,707,810
Net income
37.01b
+16.04%
8,761,048,0006,433,178,00010,918,718,0005,600,272,000-9,803,596,000-20,393,601,0002,274,880,2701,446,877,4801,961,427,000-10,933,544,000-742,474,3808,056,888,860-25,275,015,880-15,275,470,490-1,441,453,46031,891,678,69037,006,333,990
CFO
87.16b
+53.54%
14,818,649,000-1,347,997,000-11,118,758,000-11,679,166,000-18,183,738,20064,214,781,68018,724,504,4407,279,097,730-4,174,929,9206,738,635,67033,450,172,29052,109,932,81055,531,084,79063,054,366,97018,123,982,17056,764,438,56087,157,236,380
Dividend
Dec 27, 2023425 KRW/sh
Earnings
Feb 03, 2025

Profile

JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.
URL
https://www.jw-pharma.co.kr/
IPO date
Jun 14, 1976
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
748,526,708
9.38%
684,351,099
12.82%
606,584,945
10.83%
Cost of revenue
599,164,780
556,870,632
507,430,444
Unusual Expense (Income)
NOPBT
149,361,928
127,480,468
99,154,500
NOPBT Margin
19.95%
18.63%
16.35%
Operating Taxes
16,406,190
15,509,392
21,974,114
Tax Rate
10.98%
12.17%
22.16%
NOPAT
132,955,738
111,971,076
77,180,386
Net income
37,006,334
16.04%
31,891,679
-2,312.47%
(1,441,453)
-90.56%
Dividends
(8,813,671)
(7,351,968)
(7,149,500)
Dividend yield
1.01%
1.71%
1.42%
Proceeds from repurchase of equity
(260,875)
9,718,393
(13,821)
BB yield
0.03%
-2.26%
0.00%
Debt
Debt current
117,404,624
207,693,006
123,074,574
Long-term debt
80,022,081
4,951,893
124,670,982
Deferred revenue
1,325,405
(13,199,804)
Other long-term liabilities
37,193,904
18,834,089
39,765,927
Net debt
52,090,520
144,520,161
112,264,775
Cash flow
Cash from operating activities
87,157,236
56,764,439
18,123,982
CAPEX
(42,967,190)
(12,352,501)
(12,901,583)
Cash from investing activities
(63,834,270)
(18,919,160)
(22,869,152)
Cash from financing activities
(41,191,329)
(36,907,454)
27,201,590
FCF
76,776,046
145,157,435
119,782,988
Balance
Cash
92,838,028
149,678,728
65,666,061
Long term investments
52,498,157
(81,553,990)
69,814,720
Excess cash
107,909,850
33,907,183
105,151,534
Stockholders' equity
206,769,413
185,724,754
155,212,520
Invested Capital
366,330,355
406,244,334
326,090,211
ROIC
34.42%
30.58%
21.56%
ROCE
31.41%
28.87%
22.31%
EV
Common stock shares outstanding
24,605
23,922
23,208
Price
35,550.00
97.61%
17,989.72
-17.11%
21,701.88
-33.00%
Market cap
874,717,526
103.26%
430,354,166
-14.55%
503,658,381
-33.03%
EV
929,981,674
564,252,237
606,620,472
EBITDA
171,936,526
144,316,788
115,266,247
EV/EBITDA
5.41
3.91
5.26
Interest
12,561,689
9,386,791
7,336,662
Interest/NOPBT
8.41%
7.36%
7.40%